Related Experiment Video

Updated: May 24, 2026

Benefits of Cardiac Resynchronization Therapy in an Asynchronous Heart Failure Model Induced by Left Bundle Branch Ablation and Rapid Pacing
12:45

Benefits of Cardiac Resynchronization Therapy in an Asynchronous Heart Failure Model Induced by Left Bundle Branch Ablation and Rapid Pacing

Published on: December 11, 2017

Clinical effects of enhanced external counterpulsation treatment in patients with ischemic heart failure

Güliz Kozdağ1, Gökhan Ertaş, Fatih Aygün

  • 1Department of Cardiology, Faculty of Medicine, Kocaeli University, Turkey.

Anadolu Kardiyoloji Dergisi : AKD = the Anatolian Journal of Cardiology
|February 28, 2012
PubMed

Insights

Enhanced external counterpulsation (EECP) significantly improved heart function and prognostic markers in patients with coronary artery disease (CAD) and heart failure (HF). This noninvasive therapy offers a safe and effective treatment option for improving clinical outcomes in these patients.

Area of Science:

  • Cardiology
  • Noninvasive Cardiovascular Therapies

Background:

  • Coronary artery disease (CAD) and heart failure (HF) are significant cardiovascular conditions.
  • Enhanced external counterpulsation (EECP) is a noninvasive treatment option for patients with CAD and HF.

Purpose of the Study:

  • To investigate the clinical effects of EECP therapy in patients with symptomatic CAD and chronic HF.
  • To determine if EECP therapy impacts prognostic markers of HF.

Main Methods:

  • Prospective cohort study design.
  • Enrolled 68 patients with symptomatic CAD and chronic HF; 47 received EECP, 21 served as controls.
  • Statistical analysis included t tests, Mann-Whitney U, Chi-square, and Fischer exact tests.

Main Results:

  • EECP significantly improved New York Heart Association functional class and left ventricular ejection fraction.
  • EECP therapy led to significant improvements in B-type natriuretic peptide and uric acid levels.
  • Post-intervention analysis showed improvements in free-T3/free-T4 ratio and mitral annular E velocity with EECP.

Conclusions:

  • EECP treatment significantly enhances clinical parameters in patients with symptomatic CAD and chronic HF.
  • The therapy positively affects biochemical markers, many of which are prognostic indicators for HF.
  • EECP demonstrates efficacy in improving prognostic markers, supporting its role in managing symptomatic CAD and chronic HF.
Abstract

More Related Videos

Utilizing Percutaneous Ventricular Assist Devices in Acute Myocardial Infarction Complicated by Cardiogenic Shock06:10

Utilizing Percutaneous Ventricular Assist Devices in Acute Myocardial Infarction Complicated by Cardiogenic Shock

Published on: June 12, 2021

Related Concept Videos

Heart Failure VI: Adjunct Therapies01:22

Heart Failure VI: Adjunct Therapies

Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
Heart Failure VII: Nursing Interventions01:30

Heart Failure VII: Nursing Interventions

The first step in nursing management of a patient with heart failure involves thoroughly assessing the patient's medical history.Subjective Data: Obtain the patient's medical history of coronary artery disease, hypertension, myocardial infarction, and symptoms like dyspnea, orthopnea, and paroxysmal nocturnal dyspnea.Objective Data: Conduct a physical examination to identify findings such as jugular vein distention, pulmonary crackles, tachycardia, murmurs, peripheral edema, and vital signs,...
Heart Failure Drugs: β-Blockers01:22

Heart Failure Drugs: β-Blockers

β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation, vasodilation, and...
Heart Failure II: Pathophysiology01:29

Heart Failure II: Pathophysiology

Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
Cardiomyopathy II: Dilated Cardiomyopathy01:30

Cardiomyopathy II: Dilated Cardiomyopathy

Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...